SCHEMBL23928464

SCHEMBL23928464

CCCCCCCCN(C)C(=O)C(CCC)CCC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 5/20 0.41
DNM1 Q05193 3/20 0.41
CHRM1 P11229 1/20 0.40
AKR1A1 P14550 1/20 0.40
CHRM3 P20309 1/20 0.40
HTR2A P28223 1/20 0.40
HTR2C P28335 1/20 0.40
ADRA1A P35348 1/20 0.40
HRH1 P35367 1/20 0.40
DRD3 P35462 1/20 0.40
SLC6A3 Q01959 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CA2 P00918 1/20 0.40
GGPS1 O95749 3/20 0.40
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
NFKB1 P19838 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23928465 0.96 CA2 (0.46) EPHX2DNM1CA2GPR84FFAR1
SCHEMBL29180336 0.92 CA2 (0.48) EPHX2DNM1CA2GPR84FFAR1
SCHEMBL25319726 0.90 LMNA (0.43) EPHX2CA2TSHRGPR84FFAR1
SCHEMBL25317185 0.87 S1PR2 (0.46) EPHX2CA2GGPS1GPR84FFAR1
SCHEMBL25698920 0.86 CA2 (0.47) EPHX2CA2GPR84FFAR1
SCHEMBL24764590 0.86 CA2 (0.47) EPHX2CA2GPR84FFAR1
SCHEMBL25317535 0.85 CA2 (0.40) EPHX2CA2TSHRGPR84FFAR1
SCHEMBL20450716 0.85 CA2 (0.50) EPHX2DNM1CA2GGPS1
SCHEMBL20450467 0.85 CA2 (0.50) EPHX2DNM1CA2GGPS1
SCHEMBL20450713 0.85 CA2 (0.50) EPHX2DNM1CA2GGPS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578031-B2 Dissymmetric N,N-dialkylamides used particularly for separating uranium(VI) from plutonium(IV), synthesis thereof and uses of same COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÊNERGIES ALTERNATIVES (FR) 2023-02-14 US disclosed
US-20210332002-A1 DISSYMMETRIC N,N-DIALKYLAMIDES USED PARTICULARLY FOR SEPARATING URANIUM(VI) FROM PLUTONIUM(IV), SYNTHESIS THEREOF AND USES OF SAME ORANO CYCLE (FR) 2021-10-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578031-B2 Dissymmetric N,N-dialkylamides used particularly for separating uranium(VI) from plutonium(IV), synthesis thereof and uses of same NOS2, NOS1, NOS3 EPHX2 922/4885DNM1 3404/4885CHRM1 290/4885
US-20210332002-A1 DISSYMMETRIC N,N-DIALKYLAMIDES USED PARTICULARLY FOR SEPARATING URANIUM(VI) FROM PLUTONIUM(IV), SYNTHESIS THEREOF AND USES OF SAME NOS2, NOS1, NOS3 EPHX2 922/4885DNM1 3404/4885CHRM1 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.